ZURA Stock Analysis: Buy, Sell, or Hold?
ZURA - Zura Bio Limited Class A Ordinary Shares
$4.49
0.23 (5.40%)
▲
5d:
+24.03%
30d:
+6.65%
90d:
-20.11%
BUY
MODERATE Confidence
Analysis Updated: Jun 24, 2026 12:00 AM ET
Earnings: Aug 13, 2026
Get Alerted When ZURA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: ZURA shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: ZURA shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: ZURA is currently trading at $4.49, which is considered extended relative to its 30-day fair value range of $3.62 to $4.32.
Technical Outlook: Technically, ZURA is in a strong downtrend. The price is approaching resistance at $4.39. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 5.4% recently.
Market Sentiment: ZURA has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $15.67 (+267.8%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, ZURA is in a strong downtrend. The price is approaching resistance at $4.39. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 5.4% recently.
Market Sentiment: ZURA has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $15.67 (+267.8%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$3.62 -
$4.32
Company Quality Score
61/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
68.4%
All Signals
- BEARISH: Price extended above range
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+5.4%)
- BULLISH: Trading 267.8% below Wall St target ($15.67)
Trading Range Analysis
30-Day Trading Range
$3.62 -
$4.32
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$3.49
Resistance Level
$4.39
Current Trend
Strong Downtrend
Technical data as of
Jun 24, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-42.60
Wall Street Target
$15.67
(+267.8%)
Share & Embed Analysis
Last updated: June 25, 2026 10:17 AM ET
Data refreshes hourly during market hours. Next update: 11:17 AM
Data refreshes hourly during market hours. Next update: 11:17 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ZURA showing a specific setup today?
Insider Activity (6 Months)
1
Buys
0
Sells
+
Net
INSIDERS BUYING
Recent Transactions
Ai Biotechnology Llc
BUY
2000000 shares
2026-02-26
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$276 | 59 HOLD |
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$52 | 59 HOLD |
|
CYTK
Cytokinetics Inc |
STRONG BUY
21 analysts |
$105 | 61 BUY |
|
VKTX
Viking Therapeutics Inc |
STRONG BUY
19 analysts |
$93 | 60 HOLD |
|
CRNX
Crinetics Pharmaceutical… |
STRONG BUY
17 analysts |
$83 | 60 BUY |
